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ABSTRACT 
A straightforward methodology for the synthesis of conjugates between a cytotoxic 
organometallic ruthenium(II) complex and amino- and guanidinoglycosides, as potential 
RNA-targeted anticancer compounds, is described. Under microwave irradiation, the 
imidazole ligand incorporated on the aminoglycoside moiety (neamine or neomycin) 
was found to replace one triphenylphosphine ligand from the ruthenium precursor [(η6-
p-cym)RuCl(PPh3)2]
+, allowing the assembly of the target conjugates. The 
guanidinylated analogue was easily prepared from the neomycin-ruthenium conjugate 
by reaction with N,N’-di-Boc-N”-triflylguanidine, a powerful guanidinylating reagent 
that was compatible with the integrity of the metal complex. All conjugates were 
purified by semi-preparative HPLC and characterized by ESI and MALDI-TOF MS and 
NMR spectroscopy. The cytotoxicity of the compounds was tested in MCF-7 (breast) 
and DU-145 (prostate) human cancer cells, as well as in the normal HEK293 (Human 
Embryonic Kidney) cell line, revealing a dependence on the nature of the glycoside 
moiety and the type of cell (cancer or healthy). Indeed, neomycin-ruthenium conjugate 
(2) displayed moderate anti-proliferative activity in both cancer cell lines (IC50 ≈ 80 
µM), whereas that of the neamine conjugate (4) was inactive (IC50 ≈ 200 µM). 
However, the guanidinylated analogue of the neomycin-ruthenium conjugate (3) 
required much lower concentrations than the parent conjugate for equal effect (IC50 = 
7.17 µM in DU-145 and IC50 = 11.33 µM in MCF-7). Although the same ranking in 
anti-proliferative activity was found in the non-tumorigenic cell line (3 >> 2 > 4), IC50 
values indicate that aminoglycoside-containing conjugates are about 2-fold more 
cytotoxic in normal cells (e.g. IC50 = 49.4 µM for 2) than in cancer cells, whereas an 
opposite tendency was found with the guanidinylated conjugate, since its cytotoxicity in 
the normal cell line (IC50 = 12.75 µM for 3) was similar or even lower than that found 
in MCF-7 and DU-145 cancer cell lines, respectively. Cell uptake studies performed by 
ICP-MS with conjugates 2 and 3 revealed that guanidinylation of the neomycin moiety 
had a positive effect on accumulation (about 3-fold higher in DU-145 and 4-fold higher 
in HEK293), which correlates well with the higher anti-proliferative activity of 3. 
Interestingly, despite the slightly higher accumulation in the normal cell than in the 
cancer cell line (about 1.4-fold), guanidinoneomycin-ruthenium conjugate (3) was more 
cytotoxic to cancer cells (about 1.8-fold), whereas the opposite tendency applied for 
neomycin-ruthenium conjugate (2). Such differences in cytotoxic activity and cellular 
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accumulation between cancer and normal cells open the way to the creation of more 
selective, less toxic anticancer metallodrugs by conjugating cytotoxic metal-based 
complexes such as ruthenium(II) arene derivatives to guanidinoglycosides. 
 
 
KEYWORDS: ruthenium, cytotoxicity, cellular accumulation, RNA ligands, 
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INTRODUCTION 
Organometallic complexes have emerged in recent years as promising anticancer 
metallodrugs, which could well overcome cisplatin and platinum-related analogues’ 
disadvantages, mainly toxicity and drug resistance in cancer cells.1-5 Among them, 
ruthenium(II) complexes bearing a pi-bonded arene ligand are particularly interesting 
since they have shown promising anticancer activities,6-8 even in cells that had become 
resistant to cisplatin, such as Sadler’s compounds containing N,N-chelating ligands.1,9,10 
In addition, some of the Dyson’s RAPTA compounds containing pta ligand have shown 
antimetastatic activity.11,12 Their so-called “piano-stool” geometry includes an arene 
unit that stabilizes the ruthenium +2 oxidation state and confers hydrophobicity on the 
global metal complex, as well as mono- or bidentate ligands, including one or two 
leaving groups. In most cases, the release of labile chlorido ligands is triggered inside 
the cell nucleus by the low chloride concentration (4 mM vs ∼100 mM in extracellular 
fluids), allowing for the generation of the activated aqua species that possess the 
capacity to react with the biological target.13,14 
Ruthenium offers several advantages over platinum compounds, including reduced 
toxicity and the possibility of controlling the shape and the chemical and 
pharmacological properties of the complex by the adequate selection of the arene and 
the ligands at the “legs” of the “piano-stool” structure.15,16 Moreover, modification of 
the non-leaving ligands allows the metal complex to be anchored to a “tumor-targeting 
device” such as receptor-binding peptides, folic acid or estrogens.17-24 This targeted 
strategy has a tremendous potential in the development of more efficient, less toxic, 
selective metallodrugs in chemotherapy because receptors for these carrier molecules 
are over-expressed in the membrane of tumoral cells.25-28 
 
Another strategy to improve efficiency of a metal-based drug is to increase its affinity 
with its ultimate biological target. This strategy has been explored mainly with platinum 
complexes through the covalent attachment to compounds with high affinity for DNA 
(minor groove binders or intercalators) or to synthetic oligonucleotides or Peptide 
Nucleic Acids complementary to specific DNA sequences.29 The cytotoxicity of 
ruthenium(II) arene complexes, like that of platinum compounds, has been attributed 
mainly to the binding of their aquation products to DNA.7,8 However, these complexes’ 
interaction with other potential cellular competitors such as the tripeptide glutathione 
cannot be ruled out, since they are present in large intracellular concentrations and are 
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responsible for the detoxification of heavier transition metals.30 In fact, recent studies 
have revealed that DNA is not always the primary target for some ruthenium anticancer 
compounds and that they actually bind more strongly to proteins or enzymes than to 
DNA.4,31 Hence, it seems important not only to develop efficient targeting strategies to 
deliver metallodrugs selectively into cancer cells, but also to direct them towards a 
particular biological target. 
 
Although, traditionally, metal-based drugs have been designed to target DNA, in 
therapeutic terms, RNA offers several advantages over DNA as a drug target, since it is 
involved in many cellular processes, from the regulation of gene expression to protein 
synthesis.32-35 In addition, like proteins, RNA adopts complex three-dimensional 
structures that can be exploited to design specific small molecules to modulate its 
functions.36-38 In recent years, microRNAs (miRNAs) have also emerged as new 
therapeutic targets for cancer therapy since the abnormal expression of these non-coding 
small RNAs is associated with the pathogenesis of human cancer.39,40 Like other RNAs, 
miRNA precursors adopt secondary structures that can be targeted with small 
molecules, to interfere with miRNA maturation and, for instance, to manipulate miRNA 
levels.41,42 
 
With the aim of developing new metal-based anticancer drugs that could act at the level 
of RNA, we focused on the conjugation of ruthenium(II) arene complexes with small 
molecules that had the capacity to recognize selectively RNA over DNA or proteins. 
Aminoglycoside antibiotics are possibly the most commonly studied RNA 
ligands,33,36,43,44 since they have a relatively high affinity with RNA structures and are 
able to discriminate A-type from B-type duplexes.43,44 Apart from their selectivity for 
RNA, aminoglycosides possess several amino functions that are mostly protonated 
under physiological conditions, which would confer some drug-like properties on the 
metal complex, such as aqueous solubility. However, aminoglycoside antibiotics are 
known to have a more inefficient uptake by eukaryotic than by prokaryotic cells.45 This 
problem has been solved by replacing their amine functions with guanidinium groups to 
generate guanidinoglycosides,46 since these derivatives have higher efficient uptake by 
eukaryotic cells than their aminoglycoside precursors.45 In fact, guanidinylated 
neomycin is known to transport bioactive, high molecular weight cargo into the interior 
of cells.47-49 Like naturally occurring aminoglycosides, guanidinoglycosides bind RNA 
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over DNA preferentially, but they have shown higher binding affinity and selectivity 
against several RNA targets.46,50 This strategy was first explored by Tor and 
collaborators by conjugating a platinum(II) complex with neomycin B and 
guanidinoneomycin B.51 The fact that these compounds were able to selectively cross-
link an RNA structure derived from HIV Rev Response Element demonstrated that 
therapeutically relevant RNA structures could be targeted with metal complexes by 
using the appropriate glycoside.  
 
Herein, we describe for the first time the synthesis, characterization, cellular uptake and 
antiproliferative activity of conjugates between a ruthenium(II) arene complex, [(η6-p-
cym)RuCl(Im-BzCOOMe)(PPh3)]
+ (1),24 where Im-BzCOOMe refers to the methyl 
ester of the 4-(1H-imidazol-1-yl)benzoic acid, and neomycin B (2), guanidinoneomycin 
B (3) and neamine (4) (Scheme 1). In all cases, the metal complex was attached to the 
amino- or the guanidinoglycoside through the phenyl ring linked to the imidazole 
ligand. The triphenylphosphine-containing ruthenium(II) complex 1 was recently 
described as a promising anticancer lead compound, since its anti-proliferative activity 
is comparable to that of cisplatin in two tumoral cell lines, MCF-7 and DU-145.24 
Interestingly, a direct correlation was found between the cytotoxicity of its octreotide 
conjugate and the level of expression of the receptors for this peptide in the membrane 
of tumoral cells.24 
 
 
Scheme 1. Structure of the amino(guanidino)glycosides and their ruthenated conjugates. 
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MATERIALS AND METHODS 
General Procedures. Unless otherwise stated, common chemicals and solvents (HPLC 
grade or reagent grade quality) were purchased from commercial sources and used 
without further purification. Peptide grade DMF was from Scharlau. Milli-Q water was 
directly obtained from a Milli-Q system equipped with a 5000-Da ultrafiltration 
cartridge. Boc-protected amino derivative of neomycin (5)52 and trityl- and p-
methoxybenzyl-protected amino derivative of neamine (8)53 were prepared as reported 
elsewhere. Metal complexes [(η6-p-cym)RuCl(PPh3)2][PF6]54 and [(η6-p-cym)RuCl(Im-
BzCOOMe)(PPh3)][PF6] (1)
24 were synthesized according to procedures described 
elsewhere. 
NMR spectra were recorded at 25ºC on a Varian Mercury 400 MHz, Bruker 500 MHz 
or 600 MHz spectrometer, using deuterated solvents. Tetramethylsilane (TMS) was 
used as an internal reference (δ 0 ppm) for 1H spectra recorded in CDCl3 and the 
residual signal of the solvent (δ 77.16 ppm) for 13C spectra. For CD3OD, the residual 
signal of the solvent was used as a reference. 
High-Resolution MALDI-TOF mass spectra were recorded on a 4800 Plus MALDI-
TOF/TOF spectrometer (Applied Biosystems) in the positive mode, using 2,4-
dihydroxybenzoic acid as a matrix. ESI mass spectra (ESI-MS) were recorded on a 
Micromass ZQ instrument with single quadrupole detector coupled to an HPLC. High-
Resolution Electrospray mass spectra (HR ESI MS) were obtained on an Agilent 1100 
LC/MS-TOF instrument. 
Analytical reversed-phase HPLC analyses were carried out on a GraceSmart RP C18 
column (250x4 mm, 5 µm, flow rate: 1 mL/min), using linear gradients of 0.045% TFA 
in H2O (solvent A) and 0.036% TFA in ACN (solvent B). Large-scale purification was 
carried out in a Jupiter Proteo semipreparative column (250 x 10 mm, 10 µm, flow rate: 
3-4 mL/min), using linear gradients of 0.1% TFA in H2O (solvent A) and 0.1% TFA in 
ACN (solvent B). After several runs, pure fractions were combined and lyophilized.  
A [Vydac C18]-filled glass column (22x2 cm, 15-20 mm, 300 Å) was used for medium-
pressure liquid chromatography (MPLC), using aqueous and ACN solutions containing 
0.05% TFA (flow rate: 3 mL/min). Elution was carried out by connecting a piston pump 
to the mixing chamber of a gradient-forming device and to the top of the glass column. 
The mixing chamber of the gradient-forming device was the flask containing solvent A, 
which was connected through a stopcock to the flask containing solvent B. The bottom 
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of the preparative column was connected to an automatic fraction collector through a 
UV/Vis detector, which was also connected to a chart recorder using the appropriate 
ports. The column was equilibrated with 200 mL of solvent A, and 600 mL of each 
mobile phase was introduced into the appropriate compartments of the gradient-forming 
device. 
 
Synthesis and characterization of conjugates 
Boc-protected imidazole-neomycin derivative 6: 4-(1H-Imidazol-1-yl)benzoic acid 
(233 mg, 1.24 mmol) and PyBOP (643 mg, 1.24 mmol) were suspended in anhydrous 
DMF (8 mL) under Ar. Upon addition of DIPEA (840 µL, 4.94 mmol), the suspension 
rapidly dissolved (within 5 min with stirring at rt) and acquired an intense yellow color. 
This solution was added over the Boc-protected amino derivative of neomycin 5 (300 
mg, 0.25 mmol) dissolved in anhydrous DMF (10 mL). Then, the mixture was stirred at 
rt for 2 h under Ar. After evaporation in vacuo the residue was partitioned between 
AcOEt (100 mL) and H2O (100 mL). The organic phase was taken up and washed with 
H2O (2 x 100 mL) and 10 % aqueous NaHCO3 (2 x 100 mL), dried over anhydrous 
MgSO4 and filtered, and the solvent was removed in vacuo. Purification by silica gel 
flash-column chromatography (gradient: 0-15 % of MeOH in DCM) afforded the 
desired product as a white solid (120 mg, 35%). Rf (10% MeOH in DCM): 0.44; HR 
ESI MS, positive mode: m/z 1384.6985 (calcd mass for C63H102N9O25 [M+H]
+: 
1384.6988); HR MALDI-TOF MS, positive mode: m/z 1406.91 (calcd mass for 
C63H101N9NaO25 [M+Na]
+: 1406.6806); 1H NMR (500 MHz, CD3OD) δ (ppm): 8.23 
(2H, d, J=8.5 Hz), 7.93 (1H, s br), 7.79 (3H, d, J=8.5 Hz), 7.51 (1H, s br), 5.40 (1H, s 
br), 5.17 (1H, s), 4.94 (1H, s), 4.32 (1H, m), 4.24 (1H, m), 4.06 (1H, m), 3.96 (1H, m), 
3.92 (2H, m), 3.79 (1H, m), 3.75 (2H, m), 3.70 (1H, m), 3.63 (2H, m), 3.55 (3H, m), 
3.50 (2H, m), 3.32 (4H, m), 3.16 (1H, m), 1.96 (1H, m), 1.41 (55H, Boc+1H, m). 
Ruthenium-neomycin conjugate 2: 6 (100 mg, 0.07 mmol) and [(η6-p-
cym)RuCl(PPh3)2][PF6] (68 mg, 0.07 mmol) were introduced into a microwave reactor. 
After addition of a 0.4 M LiCl solution in anhydrous DMF (217 µL, 1.2 mol eq LiCl) 
and triethylamine (103 µL, 10 mol eq), the reaction mixture was diluted with 
DCM/MeOH 9:1 until a final volume of 10 mL was reached. Microwave irradiation (40 
W) was performed at 60ºC under Ar atmosphere for 40 min with continuous magnetic 
stirring. The reaction mixture was diluted with AcOEt (25 mL) and the organic phase 
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was washed with H2O (3 x 25 mL), dried over anhydrous MgSO4 and filtered, and the 
solvent was removed in vacuo.  
The crude was treated at 0ºC with a 30% TFA solution in DCM (10 mL) and allowed to 
come to rt. After 25 min at rt, the solvent was evaporated and the residue was re-
dissolved in a 1:1 H2O/MeOH mixture, lyophilized and purified by MPLC. Pure 
fractions by analytical HPLC were combined and lyophilized, affording the desired 
product as the trifluoroacetate-salt of a yellow solid (20.5 mg, 54%).  
Characterization: Rt= 14.6 min (analytical gradient: 0 to 100 % in 30 min); HR ESI MS, 
positive mode: m/z 1316.4510 (calcd mass for C61H82ClN9O13PRu [M]
+: 1316.4502), 
m/z 1054.3580 (calcd mass for C43H67ClN9O13Ru [M-PPh3]
+: 1054.3590), m/z 
1018.3827 (calcd mass for C43H66N9O13Ru [M-Cl-PPh3-H]
+: 1018.3824); HR MALDI-
TOF MS, positive mode: m/z 1280.4735 (calcd mass for C61H81N9O13PRu [M-Cl-H]
+: 
1280.47). 1H NMR (500 MHz, CD3OD) δ (ppm): 8.28 (1H, Im, s), 8.05 (2H, 2Ar Ph, d, 
J=7.5 Hz), 7.53 (2H, Im, d, J=7.0 Hz), 7.48-7.41 (17H, 2Ar Ph +15Ar PPh3, d, m), 6.12 
(1H, Ar p-cym, d, J=6.0 Hz), 5.94 (1H, Ar p-cym, t, J=5.5 Hz), 5.87 (1H, H1´´´, d, J=4.0 
Hz), 5.76 (1H, Ar p-cym, d, J=6.0 Hz), 5.47 (1H, H1´´, d, J=5.5 Hz), 5.36 (1H, H1´, s), 
5.17 (1H, Ar p-cym, d, J=6.0 Hz), 4.57 (1H, H3´´, t, J=4.5 Hz), 4.37 (1H, H4´´, m), 4.31 
(1H, H5´, m), 4.21 (1H, H4, m), 4.15 (1H, H3´, m), 4.08-3.97 (5H, 
H2´´+H3´´´+H4´´´+H5´´´+1H5´´, m), 3.91 (1H, H5, m), 3.69-3.62 (4H, 
H2´´´+1H5´´+H4´+H6, m), 3.51 (1H, H3, m), 3.44 (1H, H2´, m), 3.40-3.35 (2H, 
1H6´+1H6´´´, m), 3.29-3.20 (3H, 1H6´+1H6´´´+H1, m), 2.52 (1H, iPr, m), 2.45 (1H, 
1H2, m), 2.08 (1H, 1H2, m), 1.77 (3H, CH3, m), 1.20 (3H, CH3 
i
Pr, d, J=6.5 Hz), 1.17 
(3H, CH3 
i
Pr, d, J=6.5 Hz). 
Ruthenium-guanidinoneomycin conjugate 3: The trifluoroacetate salt of conjugate 2 
(2 mg, 0.95 µmol) was dissolved in methanol (1 mL) and reacted with N,N’-di-Boc-N”-
triflylguanidine (78 mg, 0.20 mmol) and triethylamine (140 µL, 1 mmol) for 20 days at 
rt under an Ar atmosphere. After evaporation in vacuo, the residue was treated with a 
1:1 TFA/DCM mixture and stirred for 4 h at room temperature. The reaction mixture 
was concentrated under vacuum and, after several co-evaporations from toluene, the 
crude was dissolved in 0.1% trifluoroacetic acid in water and lyophilized. Purification 
by analytical HPLC afforded the TFA salt of conjugate 3 as a yellow solid (0.77 mg, 
34%).  
Characterization: Rt= 17.0 min (analytical gradient: 0 to 100% in 30 min); HR ESI MS, 
positive mode: m/z 784.7942 (calcd mass for C67H95ClN21O13PRu [M+H]
2+: 784.7946). 
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1H NMR (600 MHz, D2O) δ (ppm): 7.93 (1H, s), 7.87 (1H, s), 7.78-7.75 (2H, m), 7.48 
(1H, d, J=8.4 Hz), 7.33-7.23 (17H, m), 5.97 (1H, Ar p-cym, d, J=6.0 Hz), 5.68 (1H, 
H1´´´, m), 5.67 (1H, Ar p-cym, m), 5.64 (1H, Ar p-cym, d, J=6.0 Hz), 5.07 (1H, H1´´, 
m), 5.04 (1H, Ar p-cym, d, J=6.0 Hz), 4.91 (1H, H1´, m), 4.30-4.24 (2H, m), 4.01-3.90 
(3H, m), 3.70-3.59 (3H, m), 3.54-3.30 (10H, m), 3.26-3.16 (2H, m), 3.05-2.98 (2H, m), 
2.30 (1H, iPr, sp, J=6.5 Hz), 1.63 (3H, CH3, s), 1.50 (1H, 1H2, q, J=12 Hz), 1.11 (1H, 
1H2, t, J=7.2 Hz), 0.98 (3H, CH3 
i
Pr, d, J=6.5 Hz), 0.93 (3H, CH3 
i
Pr, d, J=6.5 Hz). 
(Trt)4(PMB)3-protected imidazole-neamine derivative 9: 4-(1H-Imidazol-1-yl)benzoic 
acid (54 mg, 0.29 mmol) and PyBOP (149 mg, 0.29 mmol) were suspended in 
anhydrous DMF (1 mL) under Ar. On addition of DIPEA (194 µL, 1.14 mmol), the 
suspension rapidly dissolved (within 5 min with stirring at rt) and acquired an intense 
yellow color. This solution was added over the (Trt)4(PMB)3-protected amino derivative 
of neamine 8 (100 mg, 0.057 mmol) dissolved in anhydrous DMF (3 mL). Then, the 
mixture was stirred at rt for 2 h under Ar. After evaporation in vacuo the residue was 
partitioned between AcOEt (10 mL) and H2O (10 mL). The organic phase was taken up 
and washed with H2O (2 x 10 mL), brine (1 x 10 mL) and 10% aqueous NaHCO3 (1 x 
10 mL), dried over anhydrous MgSO4 and filtered, and the solvent was removed in 
vacuo. Purification by silica gel flash-column chromatography (gradient: 0-20% of 
MeOH in DCM) afforded a white solid (33 mg) that corresponds to the desired product. 
However, 9 was slightly contaminated with tris(pyrrolidin-1-yl)phosphine oxide 
according to the 1H NMR spectrum (overall yield of 9: 39.3%). Rf (10% MeOH in 
DCM): 0.45; HR ESI MS, positive mode: m/z 1920.9595 (calcd mass for C128H126N7O10 
[M+H]+: 1920.9566), m/z 1678.8498 (calcd mass for C109H112N7O10 [M-Trt+H]
+: 
1678.8470), m/z 1436.7402 (calcd mass for C90H98N7O10 [M-2Trt+H]
+: 1436.7375); 1H 
NMR (400 MHz, CDCl3) δ (ppm): 7.91 (1H, m), 7.85 (2H, m), 7.68 (6H, m), 7.45 (1H, 
m), 7.43 (1H, m), 7.38 (9H, m), 7.30 (17H, m), 7.25 (1H, m), 7.23 (2H, m), 7.15 (6H, 
m), 7.08 (5H, m), 7.00 (12H, m), 6.90 (8H, m), 6.64 (8H, m), 5.30 (1H, s), 4.51 (4H, 
m), 4.23 (1H, d, J = 10.4 Hz), 4.08 (1H, m), 3.78 (3H, s), 3.76 (3H, s), 3.73 (1H, m), 
3.69 (3H, s), 3.55 (2H, m), 3.35 (3H, m), 3.06 (1H, s), 2.82 (3H, m), 2.65 (1H, m), 2.55 
(1H, m), 2.44 (2H, m), 2.21 (2H, m), 1.48 (5H, m), 1.26 (9H, m). **signals in the 
spectrum from tris(pyrrolidin-1-yl)phosphine oxide: 3.15 ppm (10H, m) and 1.81 ppm 
(10H, m). 
Ruthenium-neamine conjugate 4: 9 (33 mg, 0.017 mmol) and [(η6-p-
cym)RuCl(PPh3)2][PF6] (24 mg, 0.026 mmol) were dissolved in a 9:1 mixture of 
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DCM/EtOH (1 mL) in a microwave reactor. After addition of a 0.4 M LiCl solution in 
anhydrous DMF (78 µL, 1.8 mol eq LiCl) and triethylamine (25 µL, 10 mol eq), the 
reaction mixture was irradiated (40 W) at 60ºC under Ar atmosphere for 1 h with 
continuous magnetic stirring. The reaction mixture was diluted with AcOEt (10 mL) 
and washed with H2O (3 x 10 mL) and brine (3 x 10 mL), dried over anhydrous MgSO4 
and filtered, and evaporated in vacuo.  
The crude was dissolved in a 1:1 mixture of TFA/anisole (25 mL) under argon. After 
stirring at rt for 15 h, MeOH (50 mL) was added and evaporated in vacuo. The resulting 
oil was partitioned between DCM (50 mL) and Milli-Q water (50 mL) and the aqueous 
phase was taken up and washed with DCM (2 x 50 mL) and lyophilized. Purification by 
semi-preparative HPLC (gradient 0 to 100% in 30 min) afforded the TFA salt of 4 as a 
yellow solid (13.4 mg, 46%).  
Characterization: Rt= 17.5 min (analytical gradient: 0 to 100% in 30 min); HR ESI MS, 
positive mode: m/z 1124.4146 (calcd mass for C56H74ClN7O7PRu [M]
+: 1124.4119); HR 
MALDI-TOF MS, positive mode: m/z 1090.5 (calcd mass for C56H73N7O7PRu [M-Cl-
H]+: 1088.43). 1H NMR (500 MHz, CD3OD) δ (ppm): 8.26 (1H, Ar Im, m), 7.98 (2H, 
2Ar Ph, d, J=9.0 Hz), 7.53 (2H, Ar Im, dt, J=6.0 Hz, J’=1.5 Hz), 7.48-7.39 (17H, 2Ar 
Ph +15H Ar PPh3, m), 6.10 (1H, Ar p-cym, dd, J=6.0 Hz, J’=1.0 Hz), 5.94 (1H, Ar p-
cym, dd, J=6.0 Hz, J’=1.5 Hz), 5.84 (1H, H1´, d, J=3.5 Hz), 5.75 (1H, Ar p-cym, dd, 
J=6.0 Hz, J’=1.0 Hz), 5.17 (1H, Ar p-cym, dt, J=6.0 Hz, J’=1.5 Hz), 4.14 (1H, H4, m), 
4.07 (3H, H5´+H3´+1H CH2-NH, m), 3.76 (1H, 1H CH2-NH, m), 3.60-3.54 (2H, 
H5+H6, m), 3.49 (1H, H3, m), 3.42-3.35 (5H, 1H6´+H4´+H2´+CH2-O, m), 3.26-3.19 
(2H, 1H6´+H1, m), 2.50 (1H, iPr, qt, J=7 Hz), 2.39 (1H, 1H2, dt, J=12 Hz, J’=4.0 Hz), 
1.99 (1H, 1H2, q, J=12 Hz), 1.76 (3H, CH3, s), 1.66 (4H, NH-CH2-CH2-CH2-CH2-CH2-, 
m), 1.43 (4H, NH-CH2-CH2-CH2-CH2-, m), 1.19 (3H, CH3 
i
Pr, d, J=7 Hz), 1.16 (3H, 
CH3 
i
Pr, d, J=7 Hz). 
 
Cytotoxicity assays in cancer cell lines 
The cytotoxicity of the conjugates and of the control compounds was determined by the 
MTT assay in the breast cancer MCF-7 cell line and the prostate carcinoma DU-145 cell 
line, as well as in human embryonic kidney 293 (HEK293) non-tumoral cells. Aliquots 
of 4,000 DU-145, 3,500 MCF-7 and 6,000 HEK293 cells were seeded onto flat-
bottomed 96-well plates. 24 h later, the cells were treated for 72 h with the compounds 
at concentrations ranging from 0 µM to 250 µM. After removal of the treatment, the 
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cells were washed with PBS and incubated for 3 additional hours with 100 µL of fresh 
culture medium together with 10 µL of MTT (Sigma-Aldrich). The medium was 
discarded and DMSO (Sigma-Aldrich) was added to each well to dissolve the purple 
formazan crystals. Plates were shaken at room temperature for 2 minutes and the 
absorbance of each well was determined on a Multiscan Plate Reader (ELX800, Biotek, 
Winooski, USA) at a wavelength of 570 nm. Three replicates were used in each 
experiment. For each treatment, cell viability was determined as a percentage of the 
control untreated cells, by dividing the mean absorbance of each treatment by the mean 
absorbance of the untreated cells. The concentration that reduces cell viability by 50% 
(IC50) was established for each compound. 
 
Ruthenium accumulation in cancer cells. For ruthenium cell uptake studies, 1.5 x 106 
DU-145 or HEK293 cells were plated in 100 mm Petri dishes and allowed to attach for 
48 h. Next, the plates were exposed to compounds 1-3 at a concentration corresponding 
to a fifth of their IC50 (DU-145: 1.3 µM for 1, 17 µM for 2 and 1.4 µM for 3; HEK293: 
0.5 µM for 1, 10 µM for 2 and 2.4 µM for 3). Additional plates were incubated with 
medium alone as negative control. After 24 h incubation, the cells were rinsed three 
times with cold PBS and harvested by trypsinization. The number of cells in each 
sample was counted manually in a hemocytometer using the Trypan Blue dye-exclusion 
test. Then the cells were centrifuged to obtain the whole cell pellet for ICP-MS analysis. 
All experiments were conducted in triplicate. 
ICP-MS analysis. The whole cell pellets were dissolved in 400 µL of concentrated 
60% v/v nitric acid, and the samples were then transferred into Wheaton v-vials (Sigma-
Aldrich) and heated in an oven at 373 K for 18 h. The vials were then allowed to cool, 
and each cell sample solution was transferred into a volumetric tube and combined with 
washings with Milli-Q water (1.6 mL). Digested samples were diluted 10 times with 
Milli-Q to obtain a final HNO3 concentration of approximately 1.2% v/v. Ruthenium 
content was analyzed on an ICP-MS Perkin Elmer Elan 6000 series machine at the 
Centres Científics i Tecnològics of the University of Barcelona. The solvent used for all 
ICP-MS experiments was Milli-Q water with 1% HNO3. The ruthenium standard (High-
Purity Standards, 1000 µg/mL + 5 µg/mL in 2% HCl) was diluted with Milli-Q water to 
100 ppb. Ruthenium standards were freshly prepared in Milli-Q water with 1% HNO3 
before each experiment. The concentrations used for the calibration curve were in all 
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cases 0, 1, 2, 5 and 10 ppb. The isotope detected was 101Ru and readings were made in 
triplicate. Rhodium was added as an internal standard at a concentration of 10 ppb in all 
samples. 
 
RESULTS  
Synthesis and characterization of ruthenium-amino(guanidino)glycoside 
conjugates. 
Conjugation of the ruthenium complex to neomycin B was planned through the 5’’-OH, 
since this primary hydroxyl group can be regioselectively converted to amino group, 
allowing the attachment of the imidazole ligand via an amide bond formation. In 
addition, this modification does not alter the number of chargeable groups that are 
essential for RNA binding and cell uptake. First, 4-(1H-Imidazol-1-yl)benzoic acid was 
coupled with the Boc-protected amino derivative of neomycin52 (5, Scheme 2) by using 
PyBOP as a coupling reagent in anhydrous DMF for 2 h at rt in the presence of DIPEA. 
The metal complex was assembled on the imidazole-derivatized neomycin (6) by 
reaction with [(η6-p-cym)RuCl(PPh3)2][PF6] (1 mol equiv) in the presence of LiCl (1.2 
mol equiv) and NEt3 (10 mol equiv) in a DMF/EtOH 9:1 mixture for 40 min at 60ºC 
under microwave irradiation. Reversed-phase HPLC analysis of the deprotected crude 
(30% TFA in DCM, 25 min rt) showed the presence of a main peak, which was isolated 
and characterized by MS as the expected conjugate 2. Hence, as previously found with 
imidazole-derivatized peptide-bound resins,24 the imidazole ligand incorporated in the 
aminoglycoside moiety is able to replace one of the two PPh3 ligands in [(η6-p-
cym)RuCl(PPh3)2]
+. However, in this case it was necessary to use microwave irradiation 
to assemble the ruthenium complex, since no evidence of the formation of the Boc-
protected intermediate 7 was obtained after prolonged heating (24 h) at 50ºC. After 
purification by reversed-phase medium-pressure liquid chromatography, the 
trifluoroacetate salt of conjugate 2 was obtained as a yellow solid (overall yield from 6: 
54%) that was unambiguously characterized by mass spectrometry and NMR 
spectroscopy.  
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Scheme 2. Synthesis of the ruthenium-neomycin and ruthenium-guanidinoneomycin 
conjugates. 
 
High-resolution ESI MS analysis of the neomycin-ruthenium conjugate 2 afforded an 
m/z value that was consistent with the calculated value of the monocharged species 
([M]+) and with the expected isotopic distribution of ruthenium (Figure 1). In addition, 
2 was fully characterized by 1H NMR spectroscopy by using 1D and 2D experiments 
(COSY and TOCSY). The region of the 1H NMR spectra between 5.0 and 8.5 ppm is 
shown in Figure 1, where signals from the ruthenium complex (p-cymene, imidazole 
and PPh3 ligands) and from the aminoglycoside moiety (anomeric H1’ protons) are 
indicated.  
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Figure 1. 1H NMR spectra of conjugate 2 (A) in CD3OD, showing the region between 4.5 and 
8.5 ppm. Expanded ESI mass spectrum of the molecular peak of 2 ([M]+), experimental (B) and 
calculated (C). 
 
Our next objective was the synthesis of the guanidinylated analogue of the neomycin-
ruthenium conjugate (compound 3 in Scheme 1), which was planned by using N,N’-di-
Boc-N”-triflylguanidine, a powerful guanidinylating reagent usually employed in the 
preparation of guanidinoglycosides.55 Conjugate 2 was dissolved in methanol and 
reacted with a large excess of N,N’-di-Boc-N”-triflylguanidine (200 mol equiv) in the 
presence of triethylamine (1000 mol equiv) at RT under an Ar atmosphere (Scheme 2). 
The reaction was very slow, especially the incorporation of the sixth guanidinium 
group, as followed by ESI MS analysis. Once the reaction reached completion (about 20 
days), the Boc-protected guanidino conjugate was treated with a TFA/DCM mixture 
(1:1) for 4 h at RT. Reversed-phase HPLC analysis revealed the presence of a main 
peak, which was isolated and characterized by high-resolution MS and NMR as the 
expected conjugate 3 (overall yield from 2: 34%). It is interesting to note that the 
ruthenium complex remained unaltered during the prolonged reaction time, which 
accounts for its high stability in solution (see below). 
 
One of the main problems of aminoglycoside antibiotics is their inherent toxicity, 
usually nephrotoxicity or ototoxicity, which are associated with non-specific 
electrostatic binding to RNA.43,44 To minimize these problems, we selected the 
pseudodisaccharide known as neamine (Scheme 1), because a reduction in the number 
A B 
C 
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of amino groups in the aminoglycoside scaffold usually gives less toxic compounds. 
This smaller aminoglycoside is still an attractive starting molecule, since it incorporates 
rings I and II of most naturally-occurring aminoglycosides, such as neomycin B, which 
are important structural motifs in the recognition of RNA targets, including rRNA, RRE 
and TAR RNA. Hence, our next objective was the synthesis of the neamine-ruthenium 
conjugate (4) by the optimized procedure used for the preparation of the neomycin 
analogue 2.  
The attachment of the metal complex was planned through the 5-hydroxyl group of the 
2-deoxystreptamine ring (Scheme 1), since the use of trityl protective groups for the 
amino functions allows the regioselective protection of all hydroxyl functions with 4-
methoxybenzyl groups, except that located at the 5- position.53 Again, the required 
imidazole-derivatized neamine (9) was obtained by reaction between 4-(1H-Imidazol-1-
yl)benzoic acid and the (Trt)4(PMB)3-protected amino derivative of neamine (8) by 
using PyBOP as a coupling reagent (Scheme 3). The metal complex was assembled on 
the imidazole ring by reacting 9 with [(η6-p-cym)RuCl(PPh3)2][PF6] in the presence of 
LiCl and NEt3 in a DMF/EtOH 9:1 mixture for 1 h at 60ºC under microwave irradiation. 
In this case, deprotection was achieved by treatment of the crude with a 1:1 mixture of 
TFA/anisole under Ar for 15 h at RT. Purification by semi-preparative HPLC afforded 
the TFA salt of conjugate 4 as a yellow solid (yield from 9: 46%), which was fully 
characterized by high-resolution ESI and MALDI-TOF MS and NMR.  
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Scheme 3. Synthesis of the ruthenium-neamine conjugate. 
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Studies on the activation of the ruthenium complex in conjugates 2 and 3 
Since the cytotoxic activity of most metallodrugs is intimately related to their hydrolysis 
behavior in aqueous media, prior to cytotoxicity studies we wanted to assess whether 
hydrolysis of the Ru-Cl bond occurs when the ruthenium complex is conjugated to the 
glycoside carrier. This process is known to facilitate the interaction of the metal with the 
biological target (e.g. nucleic acids or proteins) through the generation of 
monofunctional adducts on guanine nucleobases by the activated aqua species. 
Although anticancer activity of ruthenium(II) arene complexes has been attributed in 
most cases to DNA ruthenation, some compounds such as 1 do not experience aqueous 
hydrolysis of the Ru-Cl bond,24 which hinders the covalent interaction with the 
biological target.  
On the basis of these precedents, the stability of conjugates 2 and 3 (Scheme 1) was 
investigated in aqueous solution at a chloride concentration mimicking the typical cell 
nucleus (4 mM). As previously found with 1 or its peptide conjugate,24 reversed-phase 
HPLC analysis together with MS revealed that no hydrolysis occurred in the case of the 
ruthenium-(guanidino)neomycin conjugates on incubation at 37ºC for 48 h. 
Surprisingly, the compounds also remained unaltered upon incubation at 37ºC for 72 h 
with a large excess of glutathione (250 mol equiv) under physiologically relevant 
conditions (pH 7 phosphate buffer containing 22 mM NaCl, the cytoplasmatic 
concentration of chloride).30 These results suggest that the ruthenium moiety in the 
amino(guanidino)glycoside conjugates (2-4) does not follow the typical activation 
mechanisms of most organometallic anticancer complexes (e.g. hydrolysis of the Ru-Cl 
bond and/or redox activation through the participation of the tripeptide glutathione).14 
The presence of a bulky ligand such as triphenylphosphine might explain this behavior, 
which is different from other anticancer ruthenium(II) arene complexes such as [(η6-
biphenyl)Ru(en)Cl)]+.1,14 
 
Cytotoxicity in cancer (MCF-7 and DU-145) and normal (HEK293) cell lines 
Our next objective was to evaluate the cytotoxicity of conjugates 2, 3 and 4 to 
determine their potential as anticancer agents. Their anti-proliferative activity, together 
with that of cisplatin as positive control and the unconjugated compounds (complex 1, 
neomycin, neamine and guanidinoneomycin), was first determined in two human tumor 
cell lines, the breast cancer cell line MCF-7 and the prostate carcinoma cell line DU-
145, by using the MTT test that measures mitochondrial dehydrogenase activity as an 
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indication of cell viability (Table 1). The compounds were screened at a wide range of 
concentrations (from 0 to 250 µM) to determine the concentration that inhibits cell 
growth by 50% (IC50). The compounds that did not inhibit cell growth by more than 
50% at 250 µM were considered to be inactive. Interestingly, conjugates 2-4 were 
completely soluble in water. 
 
 IC50 (µM)/cell lines 
Compound MCF-7 DU-145 HEK293 
Cisplatin 3.04 + 0.25 3.10 + 0.00 4.63 + 1.60 
Ruthenium complex 1 3.99 + 1.45 6.48 + 0.54 2.50 + 0.71 
Ru-neomycin conjugate 2 84.67 + 5.13 84.63 + 15.87 49.40 + 17.25 
Ru-neamine conjugate 4 200.75 + 15.75 221.67 + 3.33 125.00 + 2.02 
Neomycin or neamine > 250 > 250 > 250 
Ru-guanidinoneomycin conjugate 3 11.33 + 2.56 7.17 + 0.29 12.75 + 1.32 
Guanidinoneomycin  > 250 > 250 > 250 
 
Table 1. Sensitivity of tumor MCF-7 and DU-145 cells and of non-tumorigenic HEK293 cells 
to cisplatin, compounds 1-4 and control amino(guanidino)glycosides. The concentration of the 
compounds that inhibits cells viability by 50% (IC50) after 72 h was determined by means of the 
MTT assay. Each value represents the mean of three independent experiments + standard error.  
 
The concentration-response curves, plotted in Figure 2, revealed that the cytotoxic 
activity of conjugates 2-4 was very dependent on the nature of the glycoside moiety in 
these cell lines. As previously reported,24 the effectivity of the complex [(η6-p-
cym)RuCl(Im-BzCOOMe)(PPh3)]
+ (1) was comparable to that of cisplatin and slightly 
higher in MCF-7 cells than in DU-145 cells, showing IC50 values of 3.99 + 1.45 µM and 
6.48 + 0.54 µM, respectively (Table 1). Neomycin-ruthenium conjugate 2 had moderate 
anti-proliferative activity in both cell lines (IC50≈ 80), but its guanidinylated analogue 
(3) was highly cytotoxic (IC50= 11.33 + 2.56 in MCF-7 cells and IC50= 7.17 + 0.29 in 
DU-145 cells), with an IC50 value similar to that of complex 1 in the prostate cancer cell 
line. However, conjugation of the ruthenium complex to the small neamine 
aminoglycoside led to a strong decrease in cytotoxic activity (IC50≈ 200). Interestingly, 
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neither the aminoglycosides alone (neomycin or neamine) nor guanidinoneomycin were 
found to be cytotoxic (IC50 > 250). 
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Figure 2. Cytotoxic effect of compounds 1-3 in the DU-145, MCF-7 and HEK293 cell lines. 
Cells were treated for 72 h with the indicated concentrations of each compound. Cell viability 
was determined by the MTT assay. Each point in the graphs represents the mean of three 
independent experiments ± SD. 
 
Despite the promising anticancer activities of the ruthenium-glycoside conjugates, 
particularly those of guanidinoneomycin conjugate 3, an efficient targeted strategy 
requires that the potential anticancer drug must be less toxic to normal cells than to 
tumor cells. Otherwise, such anticancer agents generate undesired side-effects, as 
current platinum drugs in clinical use do. 
To assess the conjugates’ selectivity for tumor cells rather than normal cells, we 
determined the cell viability of a non-tumorigenic HEK293 cell line, in the presence of 
conjugates 2-4. To our surprise, ruthenium complex 1 (IC50= 2.50 µM) was found more 
cytotoxic in the normal cell line than in the two cancer cell lines, whereas cisplatin 
cytotoxicity was similar (IC50= 4.63 µM) (Table 1). Again, control aminoglycosides and 
guanidinoneomycin were found to be non-cytotoxic (IC50 > 250). As shown in Figure 2, 
the cytotoxicity of the ruthenium-glycoside conjugates against HEK293 cells can be 
ranked in the following order: 3 >> 2 > 4, which reproduces the tendency found in 
cancer cell lines. Interestingly, although control complex 1 and aminoglycoside-
ruthenium conjugates (2 and 4) were more cytotoxic in the normal cell line than in both 
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cancer cell lines, this tendency was reversed for the guanidinylated conjugate (3), which 
was much less active in HEK293 than in DU-145 cells. 
 
Cell uptake in DU-145 and HEK293 cell lines 
To gain insight into the involvement of the glycoside moiety in the cytotoxic activity of 
the compounds, the cell uptake of the control ruthenium complex (1) and of the 
neomycin-ruthenium (2) and guanidinoneomycin-ruthenium (3) conjugates was 
investigated in the prostate cancer cell line and in the normal cell line. Ruthenium 
accumulation (determined here as the net effect of influx and efflux of Ru) in both cell 
lines was quantified by inductively-coupled plasma mass spectrometry (ICP-
MS)24,56,57,58 after a 24 h exposure to the compounds at equicytotoxic concentrations, 
which were in all cases a fifth of their IC50 values in each cell line.  
 
As shown in Figure 3, the intracellular level of ruthenium after exposure to neomycin 
conjugate 2 (107.14 ± 8.93 pmol Ru/106 cells) was substantially higher in the DU-145 
cell line than guanidinylated analogue 3 (24.10 ± 0.72 pmol Ru/106 cells) was, whereas 
a similar level was obtained in the HEK293 cell line for both compounds (63.75 ± 8.46 
pmol Ru/106 cells for 2 and 58.02 ± 3.95 pmol Ru/106 cells for 3).  
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Figure 3. Ruthenium uptake in DU-145 and HEK293 cell lines after 24 h exposure to 
equicytotoxic concentrations of compounds 1-3. The ruthenium content is related to the cell 
number. Results are means of three independent samples and are expressed as mean + SD.  
 
On the basis of the amount of intracellular ruthenium after exposure to compounds 1-3, 
the molar intracellular concentration was calculated by considering the mean cellular 
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volume, as previously reported by Osella et al.59 The accumulation ratio was obtained 
from the ratio between the intracellular concentration and the concentration of the 
compounds in the extracellular medium at the beginning of the incubation period 
(IC50/5). As shown in Table 2, the accumulation ratio of the neomycin-ruthenium 
conjugate (2) was similar in both cell lines. However, the accumulation ratio of the 
guanidinylated analogue (3) was much higher than that of 2 both in the cancer DU-145 
cell line (about 3-fold) and in the non-tumorigenic HEK293 cell line (about 4-fold). 
Hence, these results are consistent with the generally accepted idea that the 
incorporation of guanidinium groups in a molecule facilitates its internalization through 
cell membrane,60-62 such as in the case of cell-penetrating peptides. As previously 
mentioned, cell uptake studies with amino- and guanidinoglycosides had demonstrated 
an approximately 20-fold internalization enhancement of neomycin upon 
guanidinylation.45 In fact, guanidinoneomycin shows similar or even better cell uptake 
efficiency than some polyarginine-containing peptides,45,60,61,62 which has been 
attributed to the semi-rigid pre-organization of the guanidinium groups on the glycoside 
core.45 Accordingly, ICP-MS accumulation studies with conjugates 2 and 3 showed the 
same tendency in both cell lines, since guanidinylation of the neomycin moiety leads to 
a compound (conjugate 3) with greater accumulation than its amino precursor 
(conjugate 2). Moreover, it should be noted that accumulation of the guanidinylated 
analogue (3) is about 1.4-fold higher in the normal cell than in the tumor cell, whereas 2 
is accumulated at the same ratio in both cell lines. 
 
Regarding the parent complex (1), as shown in Figure 3, the intracellular level of 
ruthenium in DU-145 cells (240.86 ± 84.40 pmol Ru/106 cells) was much higher than in 
HEK293 cells (27.64 ± 2.29 pmol Ru/106 cells). Similarly, the accumulation ratio was 
about 3-fold higher in DU-145 than in HEK293 cells (Table 2), which indicates higher 
accumulation in the prostate cancer cell line than in the normal cell line. In 
consequence, we can conclude that conjugation of the ruthenium complex through the 
imidazole ligand to a hydrophilic molecule, either neomycin or guanidinoneomycin, 
leads to compounds (2 and 3) with reduced accumulation in both cell lines, particularly 
in the case of conjugate 2, since the incorporation of the guanidinium groups in the 
glycoside moiety seems to ameliorate this reduction. 
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Finally, the fact that in all cases the intracellular concentrations were greater than the 
extracellular concentrations indicates an active cell uptake process for all the 
compounds, particularly in the case of complex 1 and, to a lesser extent, its 
guanidinoneomycin conjugate 3. 
 
 Intracellular concentration 
(µM) 
Accumulation 
ratio 
Compound / Cell line DU-145 HEK293 DU-145 HEK293 
Ruthenium complex 1 120.40 13.82 80.29 27.64 
Ru-neomycin 2 53.57 31.87 3.15 3.19 
Ru-guanidinoneomycin 3 12.05 29.01 8.61 12.09 
 
Table 2. Intracellular ruthenium concentrations determined in DU-145 and HEK293 cells after 
exposure to compounds 1-3 for 24 h at a concentration that was a fifth of their IC50 value. The 
volume of a single cell was considered to be about 2 pL.63 Accumulation ratio59 represents the 
ratio between the intracellular Ru concentration and the Ru concentration in the extracellular 
medium at the beginning of the incubation period (DU-145: 1: 1.5 µM, 2: 17 µM, 3: 1.4 µM; 
HEK293: 1: 0.5 µM, 2: 10 µM, 3: 2.4 µM). 
 
DISCUSSION 
Current research efforts in metal-based anticancer complexes have focused on the 
development of new compounds, with the aim of overcoming the high toxicity and 
sensitivity to resistance of platinum-based drugs in clinical use, such as cisplatin and its 
analogues.1-8 Organometallic complexes, in particular ruthenium(II) arene complexes, 
have attracted attention because of their promising cytotoxic activities in several tumour 
cell lines, including cisplatin-resistant cells.6-12 In medicinal chemistry terms, their 
“piano-stool” structure allows the optimization of lead compounds through structure-
activity relationship studies by modifying ligands around the metallic center.15-16 
Among such modifications, derivatization of non-leaving ligands with a carrier 
molecule has tremendous potential to generate selective, less toxic metallodrugs. The 
potential of this targeted strategy is particularly promising when metal complexes, 
either organometallic or classical coordination compounds, are attached to 
biomolecules17-24 whose receptors are overexpressed on the membrane of tumoral 
cells25-28 or to organic molecules with high affinity with a given biological target 
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(proteins or nucleic acids).29 Besides improving selectivity against cancer cells or 
affinity towards the ultimate target, such modified ligands are also expected to generate 
hybrid compounds with better pharmacological properties than the original metal 
complex, such as aqueous solubility or cellular uptake.  
 
This paper reports the effect of conjugating an anticancer ruthenium(II) arene complex 
(1) to amino- and guanidinoglycosides on the cytotoxic activity and cell uptake of the 
resulting hybrid compounds in cancer and normal cells. The ultimate aim of this project 
is to develop novel metal-based anticancer compounds with reduced toxicity and side 
effects that might have RNA as a final biological target. The fact that amino- and 
guanidinoglycosides are known to be selective RNA binders, might facilitate the 
interaction of the ruthenium moiety with potential RNA targets involved in the 
pathogenesis of cancer, such as miRNAs or their precursors (pre-miRNAs). For the 
synthesis of neomycin- (2) and neamine-ruthenium conjugates (4), the imidazole ligand 
incorporated on the suitably-protected aminoglycoside moieties was reacted under 
microwave irradiation with the complex [(η6-p-cym)RuCl(PPh3)2]+ (Scheme 1). For the 
guanidinylated analogue of the neomycin conjugate (3), the use of N,N’-di-Boc-N”-
triflylguanidine was found compatible with the integrity of the ruthenium moiety. After 
TFA deprotection, all conjugates were isolated by semipreparative HPLC (overall 
yields: 45-55%) and fully characterized by high resolution MS and NMR spectroscopy.  
 
The cytotoxicity of conjugates 2-4 together with that of cisplatin, complex 1 and control 
amino- and guanidinoglycosides was tested in two human cancer cell lines, MCF-7 
(breast) and DU-145 (prostate), as well as in a normal cell line, HEK293 (human 
embryonic kidney). As shown in Table 1, the cytotoxic activity of the ruthenium-
glycoside conjugates against cancer and normal cells can be ranked in the following 
order: 3 >> 2 > 4. The fact that both natural aminoglycoside antibiotics, neamine and 
neomycin, and guanidinoneomycin were found to be non-cytotoxic in all cell lines (IC50 
> 250) indicates that the anticancer activity of compounds 2-4 is provided by the 
ruthenium moiety. However, an accurate analysis of the IC50 values of the compounds 
reveals that, as well as the ruthenium or the glycoside moieties, the nature of the cell 
(tumoral or healthy) is another key factor to be considered. Two important observations 
can be drawn when comparing IC50 values of these compounds in the normal cell line 
with those in cancer cells. On the one hand, ruthenium-aminoglycoside conjugates (2 
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and 4) were more cytotoxic in the non-tumorigenic cell line than in cancer cells. 
Effectively, their anti-proliferative activity in HEK293 cells was increased by about 
two-fold in both cases (e.g. IC50 ≈ 80 µM for conjugate 2 in both cancer cell lines vs 
IC50= 49.4 µM for 2 in the normal cell line). On the other hand, the guanidinylated 
conjugate 3 was about two-fold less cytotoxic in the healthy cell line than in the DU-
145 cell line (e.g. IC50 = 12.75 µM vs IC50 = 7.17 µM, respectively), whereas a similar 
IC50 value was obtained when compared with the MCF-7 cell line (IC50 = 11.33 µM), 
revealing that the response to 3 is also related to the nature of the cancer cells. These 
results indicate that aminoglycoside-containing conjugates 2 and 4 show the same 
behavior as their parent ruthenium complex 1, since their cytotoxicity in normal cells 
was always greater than in cancer cells. However, this tendency was inverted with the 
guanidinylated analogue of the neomycin-ruthenium conjugate, since the anti-
proliferative activity of 3 in cancer cells was similar to or even higher than in a normal 
cell line.  
 
Such differences in cytotoxic activity for each compound in a particular cell line, either 
normal or tumoral, could be interpreted in terms of cell uptake and accumulation 
efficiency. First, the nature of the aminoglycoside moiety seems to be an important 
factor, since the cytotoxicity of the neomycin-ruthenium conjugate (2) in the three cell 
lines is about 2.5-fold higher than that of the neamine-containing conjugate (4). 
Although both aminoglycosides are polycations at physiological pH, the greater number 
of ammonium groups in neomycin than in neamine (six vs four) might favor 
accumulation of conjugate 2, resulting in a slightly greater antitumoral activity. Second, 
the fact that the cytotoxicity of the guanidinylated conjugate (compound 3) in the three 
cell lines is substantially higher than that of the parent aminoglycoside conjugate 
(compound 2) (7-fold in MCF-7 cells, 12-fold in DU-145 cells and 4-fold in HEK293 
cells) could be attributed to greater permeability through cell membranes, a property 
that might facilitate its accumulation in the cell and, for instance, higher anti-
proliferative activity. Hence, an apparently good correlation between the expected 
glycoside uptake efficiency in eukaryotic cells (guanidinoneomycin >> neomycin > 
neamine) and cytotoxic activity (3 >> 2 > 4) can be established in all cell lines, although 
this does not explain the differences between normal and cancer cells in anti-
proliferative activity of the conjugates.  
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Ruthenium accumulation studies performed by ICP-MS with neomycin (2) and 
guanidinoneomycin (3) conjugates in DU-145 and HEK293 cells clearly support the 
above conclusions. As shown in Table 2, guanidinylation of the aminoglycoside moiety 
leads to a compound (3) with higher accumulation than that of its amino precursor 2. 
Indeed, the accumulation ratio of 3 in the cancer cell line was about 3-fold greater than 
that of 2, whereas this tendency increased even more in the normal cell line (about 4-
fold). These results indicate that guanidinylation of the amino functions at the 
aminoglycoside moiety in conjugate 2 had a positive effect on cell uptake, thus 
improving intracellular accumulation. Moreover, it should be noted that the 
accumulation ratio of conjugate 3 in the normal cell line was 1.4-fold higher than in the 
cancer cell line, thus revealing behavior the opposite of its amino precursor 2, which 
was equally accumulated in both cell lines, or that of control complex 1, which 
accumulated at a higher proportion (about 3-fold) in DU-145 than in HEK293.  
 
On the one hand, recent studies have revealed that guanidinoneomycin uptake in CHO 
cells is mediated by cell-surface heparin-sulfate proteoglycans, which has been used to 
transport large bioactive cargo into cells at low concentration (nM order) in a selective 
proteoglycan-dependent manner.47-49 Thus, we may speculate that differences in the 
expression level and/or in the composition of proteoglycan receptors on the cell 
membrane surface between cancer cells and normal cells would be responsible for such 
differences in the accumulation ratio of 3 between DU-145 and HEK293 cells.64 
 
On the other hand, the fact that neomycin- and guanidinoneomycin-ruthenium 
conjugate’s accumulations were lower than that of the parent ruthenium complex 1 also 
indicates that conjugation to polar, polycationic glycosides results in reduced cell 
uptake in both cell lines, although this reduction was more dramatic in the cancer cell 
line. It is well known that lipophilic compounds can cross cell membranes more readily 
than hydrophilic compounds, which results in increased intracellular accumulation. This 
is also true for ruthenium(II) arene complexes since an increase in their lipophilicity, for 
example by increasing the size of the arene ligand, correlates with greater cytotoxicity.65 
Accordingly, the decrease in accumulation of complex 1 when conjugated to neomycin 
or guanidinoneomycin could be attributed to an overall decrease in the lipophilicity of 
the compound induced by the highly hydrophilic glycoside moiety, which would 
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therefore diminish cell uptake. Although the lipophilicity provided by the ruthenium 
complex (e.g. p-cymene and PPh3 ligands) may modulate the ability of 
amino(guanidino)glycosides to cross cell membranes when conjugated together, these 
results seem to indicate that the glycoside moiety, particularly in the case of 
guanidinoneomycin, has a fundamental weight in the cell uptake of the conjugates.  
 
Overall, on the basis of cytotoxicity and cell uptake studies, in DU-145 cells there is a 
correlation between accumulation (1 >> 3 > 2) and anti-proliferative activity (1 ≈ 3 >> 
2). The same tendency was found in the case of the normal cell line, since the cytotoxic 
activity ranking (1 > 3 >> 2) follows that of cellular accumulation data (1 > 3 >> 2). 
Interestingly, despite the fact that neomycin-ruthenium conjugate (2) accumulation was 
similar in both cell lines, its anti-proliferative activity was higher in the normal cell than 
in the tumor cell (about 1.7-fold). An opposite tendency was found for the 
guanidinylated analogue (3), since the cytotoxic activity was higher in the tumor cell 
line than in the normal cell line (about 1.8-fold), although the accumulation ratio in the 
normal cell was slightly higher (about 1.4-fold). These results suggest that the glycoside 
moiety cannot be seen as a simple carrier that modulates the lipophilicity of the 
anticancer ruthenium(II) arene complex and, for instance, cell uptake, but rather as a 
dynamic moiety that also modulates the anti-proliferative activity of the metal fragment, 
depending on the cell type. Indeed, the fact that the anti-proliferative activity of 3 in the 
DU-145 cancer cells was higher than in the HEK293 normal cells, with a lower 
accumulation ratio, suggests that guanidinoneomycin provides some kind of selectivity 
against cancer cells. This hypothesis is supported by the greater cytotoxicity of 
ruthenium complex 1 or its neomycin conjugate 2 in normal cells than in cancer cells, 
despite the fact that their accumulation in normal cells is much lower than (1) or similar 
to (2) that found in cancer cells. Hence, conjugation to guanidinoneomycin leads to a 
compound (3) with reduced cytotoxicity against normal cells but with a similar anti-
proliferative activity to that of the parent ruthenium complex 1 in DU-145 cells.  
 
Finally, we cannot rule out the possibility that amino(guanidino)glycoside conjugation 
may also modify not only cell uptake in cancer and normal cells, but also the 
mechanism of action of the ruthenium complex or its biological target. As previously 
mentioned, guanidinoglycosides have higher binding affinity with RNA sequences than 
their parent aminoglycosides do. Among aminoglycosides, neomycin derivatives bind 
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stronger RNA structures than neamine-containing compounds. Hence, given the 
significant differences in cytotoxicity of the conjugates in both cancer cell lines (IC50 ≈ 
7-11 µM for 3, IC50 ≈ 80 µM for 2 vs IC50 ≈ 200 µM for 4) and in the normal cell line 
(IC50 ≈ 12 µM for 3, IC50 ≈ 50 µM for 2 vs IC50 ≈ 125 µM for 4), we may well speculate 
about the involvement of RNA as a target for these conjugates, since there is close 
correlation between their anti-proliferative activity (3 >> 2 > 4) and the RNA binding 
affinity of the glycoside moiety (guanidinoneomycin >> neomycin > neamine). The fact 
that the ruthenium moiety in conjugates 2 and 3 does not follow the typical activation 
mechanisms of most anticancer organometallic ruthenium complexes (aqueous 
hydrolysis of the Ru-Cl bond and/or glutathione mediated redox activation) suggests 
that ruthenation at RNA nucleobases would not occur. However, binding to this 
biological target could be based on non-covalent interactions such as electrostatic forces 
and/or hydrogen bonds between the negatively charged skeleton of RNA and the 
polycationic glycoside moiety. Moreover, aromatic ligands from the ruthenium complex 
(phenyl rings in PPh3 and p-cymene) could interact with RNA through intercalation or 
stacking with nucleobases.  
 
In conclusion, the overall results demonstrate the potential of conjugating anticancer 
metal complexes, in particular organometallic ruthenium(II) complexes, to 
aminoglycosides, especially to their guanidinylated derivatives, to generate anticancer 
metal-based drugs with new modes of action. As far as we are aware, such differences 
between cancer and healthy cells in the cytotoxic activity of 
amino(guanidino)glycosides conjugated to a ruthenium complex are unprecedented and 
open the way to the use of guanidinoglycosides to deliver metal-based anticancer agents 
selectively into tumor cells, with the aim of developing new drugs with reduced toxicity 
and side-effects. Modifications on the aminoglycoside scaffold, on the metal complex or 
its properties, or in the number of guanidinium groups might lead to increasing such 
differences in cytotoxic activity between cancer and normal cells. Moreover, the use of 
cleavable linkers in the biological media or metal complexes that might be selectively 
activated (e.g. via irradiation) is expected to improve their potential as anticancer drugs. 
Since aminoglycosides and their guanidinylated derivatives might be accumulated in 
some specific cellular compartments such as lysosomes, this strategy would facilitate 
the detachment of the metallodrug from the glycoside carrier, thus increasing the 
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effective concentration of the anticancer active species. Further work is in progress to 
investigate the anticancer activity of these compounds in a wide panel of tumoral cells, 
as well as to establish their mechanism of action and if RNA is involved as a drug 
target.  
 
 29
ASSOCIATED CONTENT 
Supporting Information  
High-resolution ESI MS and NMR spectra of conjugates 2-4 and of intermediates 6 and 
9. Reversed-phase HPLC traces of pure conjugates. This information is available free of 
charge via the Internet at http://pubs.acs.org. 
 
AUTHOR INFORMATION 
Corresponding Author 
*Vicente Marchán: Phone +34 934021249, Fax +34933397878, E-mail 
vmarchan@ub.edu 
 
ACKNOWLEDGEMENTS 
This research was supported by funds from Spain’s Ministerio de Ciencia e Innovación 
(grant CTQ2010-21567-C02-01), the Generalitat de Catalunya (2009SGR208), the 
Instituto de Salud Carlos III (grants RD06/0020/0041) and the Programa 
d’Intensificació de la Recerca (UB). 
 
REFERENCES 
(1) Peacock, A. F. A.; Sadler, P. J. Medicinal organometallic chemistry: Designing 
metal arene complexes as anticancer agents. Chem. Asian J. 2008, 3, 1890-1899.  
(2) Hartinger, C. G; Dyson, P. J. Bioorganometallic chemistry-from teaching paradigms 
to medicinal applications. Chem. Soc. Rev. 2009, 38, 391-401. 
(3) Casini, A.; Hartinger, C. G.; Nazarov, A.; Dyson, P. J. Organometallic antitumour 
agents with alternative modes of action. Top. Organomet. Chem. 2010, 32, 57-80. 
(4) Gasser, G.; Ott, I.; Metzler-Nolte, N. Organometallic anticancer compounds. J. Med. 
Chem. 2011, 54, 3-25. 
(5) Noffke, A. L.; Habtemariam, A.; Pizarro, A. M.; Sadler, P. J. Designing 
organometallic compounds for catalysis and therapy. Chem. Commun. 2012, 48, 5219-
5246. 
(6) Levina, A.; Mitra, A; Lay, P. A. Recent developments in ruthenium anticancer 
drugs. Metallomics 2009, 1, 458-470.  
(7) Süss-Fink, G. Arene ruthenium complexes as anticancer agents. Dalton Trans. 2010, 
39, 1673-1688. 
 30
(8) Bergamo, A.; Sava, G. Ruthenium anticancer compounds: myths and realities of the 
emerging metal-based-drugs. Dalton Trans. 2011, 40, 7817-7823. 
(9) Yan, K. Y.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Organometallic chemistry, 
biology and medicine: ruthenium arene anticancer complexes. Chem. Commun. 2005, 
38, 4764-4776.  
(10) Kisova, A.; Zerzankova, L.; Habtemariam, A.; Sadler, P. J.; Brabec, V.; 
Kasparkova, J. Differences in the Cellular Response and Signaling Pathways between 
Cisplatin and Monodentate Organometallic Ru(II) Antitumor Complexes Containing a 
Terphenyl Ligand. Mol. Pharm. 2011, 8, 949-957. 
(11) Allardyce, C. S.; Dyson, P. J.; Ellis, D. J.; Heath, S. L. [Ru(η6-p-cymene)Cl2(pta)] 
(pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane): a water soluble compound that 
exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem. 
Commun. 2001, 15, 1396-1397.  
(12) Scolaro, C.; Bergamo, A.; Brescacin, L.; Delfino, R.; Cocchietto, M.; Laurenczy, 
G.; Geldbach, T. J.; Sava, G.; Dyson, P. J. In Vitro and in Vivo Evaluation of 
Ruthenium(II)-Arene PTA Complexes. J. Med. Chem. 2005, 48, 4161-4171. 
(13) Wang, F.; Chen, H.; Parsons, S.; Oswald, I. D. H.; Davidson, J. E.; Sadler, P. J. 
Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity 
and X-ray structures of aqua adducts. Chem. Eur. J. 2003, 9, 5810-5820.  
(14) Pizarro, A. M.; Habtemariam, A.; Sadler, P. J. Activation mechanisms for 
organometallic anticancer complexes. Top. Organomet. Chem. 2010, 32, 21-56. 
(15) Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. 
Antitumor metal compounds: more than theme and variations. Dalton Trans. 2008, 2, 
183-194.  
(16) Smith, G. S.; Therrien, B. Targeted and multifunctional arene ruthenium 
chemotherapeutics. Dalton Trans. 2011, 40, 10793-10800. 
(17) Gross, A.; Metzler-Nolte, N. Synthesis and characterization of a ruthenocenoyl 
bioconjugate with the cyclic octapeptide octreotate. J. Organomet. Chem. 2009, 694, 
1185-1188.  
(18) Metzler-Nolte, N. Biomedical applications of organometal-peptide conjugates. 
Top. Organomet. Chem. 2010, 32, 195-217. 
(19) Puckett, C. A.; Barton, J. K. Targeting a ruthenium complex to the nucleus with 
short peptides. Bioorg. Med. Chem. 2010, 18, 3564-3659. 
 31
(20) Splith, K.; Hu, W.; Schatzschneider, U.; Gust, R.; Ott, I.; Onambele, L. A.; Prokop, 
A.; Neundorf, I. Protease-activatable organometal-peptide bioconjugates with enhanced 
cytotoxicity on cancer cells. Bioconjugate Chem. 2010, 21, 1288-1296. 
(21) Puckett, C. A.; Barton, J. K. Targeting a ruthenium complex to the nucleus with 
short peptides. Bioorg. Med. Chem. 2010, 18, 3564-3659. 
(22) Ruiz, J.; Rodríguez, V.; Cutillas, N.; Espinosa, A.; Hannon, M. J. A potent 
ruthenium(II) antitumor complex bearing a lipophilic levonorgestrel group. Inorg. 
Chem. 2011, 50, 9164-9171. 
(23) Barragán, F.; López-Senín, P.; Salassa, L.; Betanzos-Lara, S.; Habtemariam, A.; 
Moreno, V.; Sadler, P. J.; Marchán, V. Photocontrolled DNA binding of a receptor-
targeted organometallic ruthenium(II) complex. J. Am. Chem. Soc. 2011, 133, 14098-
14108. 
(24) Barragán, F.; Carrion, D.; Gómez-Pinto, I.; González-Cantó, A.; Sadler, P. J.; de 
Llorens, R.; Moreno, V.; González, C.; Massaguer, A.; Marchán, V. Somatostatin 
subtype 2 receptor-targeted metal-based anticancer complexes. Bioconjugate Chem. 
2012, 23, 1838-1855. 
(25) Mezo, G.; Manea, M. Receptor-mediated tumor targeting based on peptide 
hormones. Expert. Opin. Drug. Deliv. 2010, 7, 79-96.  
(26) Xia, W.; Low, P. S. Folate-targeted therapies for cancer. J. Med. Chem. 2010, 53, 
6811-6824. 
(27) Chen, G. G.; Zeng, Q.; Tse, G. M. K. Estrogen and its receptors in cancer. Med. 
Res. Rev. 2008, 28, 954-974. 
(28) Ang, W. H.; Dyson, P. J. Classical and non-classical ruthenium-based anticancer 
drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem. 2006, 4003-4018. 
(29) van Zutphen, S.; Reedijk, J. Targeting platinum anti-tumour drugs: Overview of 
strategies employed to reduce systemic toxicity. Coord. Chem. Rev. 2005, 249, 2845-
2853. 
(30) Wang, F.; Xu, J.; Habtemariam, A.; Bella, J.; Sadler, P. J. Competition between 
Glutathione and Guanine for a Ruthenium(II) Arene Anticancer Complex: Detection of 
a Sulfenato Intermediate. J. Am. Chem. Soc., 2005, 127, 17734-17743. 
(31) Wu, B.; Ong, M. S.; Groessl, M.; Adhireksan, Z.; Hartinger, C. G.; Dyson, P. J.; 
Davey, C. A. A Ruthenium Antimetastasis Agent Forms Specific Histone Protein 
Adducts in the Nucleosome Core. Chem. Eur. J. 2011, 17, 3562-3566. 
 32
(32) Gallego, J.; Varani, G. Targeting RNA with Small-Molecule Drugs: Therapeutic 
Promise and Chemical Challenges. Acc. Chem. Res. 2001, 34, 836-843.  
(33) Tor, Y. Targeting RNA with small molecules. ChemBioChem. 2003, 4, 998-1007. 
(34) Sharp, P. A. The centrality of RNA. Cell 2009, 136, 577-580.  
(35) Georgianna, W. E.; Young, D. D. Development and utilization of non-coding 
RNA-small molecule interactions. Org. Biomol. Chem., 2011, 9, 7969-7978. 
(36) Thomas, J. R.; Hergenrother, P. J. Targeting RNA with small molecules. Chem. 
Rev. 2008, 108, 1171-1224.  
(37) Aboul-da, F. Strategies for the design of RNA-binding small molecules. Future 
Med. Chem. 2010, 2, 93-119. 
(38) Guan, L.; Disney, M. D. Recent advances in developing small molecules targeting 
RNA. ACS Chem. Biol. 2012, 7, 73-86. 
(39) Kota, S. K.; Balasubramanian, S. Cancer therapy via modulation of microRNA 
levels: a promising future. Drug Discov. Today, 2010, 15, 733-740.  
(40) Gandellini, P.; Profumo, V.; Folini, M.; Zaffaroni, N. MicroRNAs as new 
therapeutic targets and tools in cancer. Expert Opin. Ther. Targets 2011, 15, 265-279. 
(41) Gumireddy, K.; Young, D. D.; Xiong, X.; Hogenesch, J. B.; Huang, Q.; Deiters, A. 
Small-molecule inhibitors of microRNA miR-21 function. Angew. Chem. Int. Ed. 2008, 
47, 7482-7484.  
(42) Deiters, A. Small molecule modifiers of the microRNA and RNA interference 
pathway. AAPP J. 2010, 12, 51-60. 
(43) Chittapragada, M.; Roberts, S.; Ham, Y. W. Aminoglycosides: molecular insights 
on the recognition of RNA and aminoglycoside mimics. Perspect. Med. Chem. 2009, 3, 
21-37.  
(44) Houghton, J. L.; Green, K. D.; Chen, W.; Garneau-Tsodikova, S. The future of 
aminoglycosides: the end or renaissance? ChemBioChem 2010, 11, 880-902. 
(45) Luedtke, N. W.; Carmichael, P.; Tor, Y. Cellular Uptake of Aminoglycosides, 
Guanidinoglycosides, and Poly-arginine. J. Am. Chem. Soc. 2003, 125, 12374-12375. 
(46) Luedtke, N. W.; Baker, T. J.; Goodman, M.; Tor, Y. Guanidinoglycosides: A 
Novel Family of RNA Ligands. J. Am. Chem. Soc. 2000, 122, 12035-12036.  
(47) Elson-Schwab, L.; Garner, O. B.; Schuksz, M.; Crawford, B. E.; Esko, J. D.; Tor, 
Y. Guanidinylated neomycin delivers large, bioactive cargo into cells through a heparan 
sulfate-dependent pathway. J. Biol. Chem. 2007, 282, 13585-13591.  
 33
(48) Sarrazin, S.; Wilson, B.; Sly, W. S.; Tor, Y.; Esko, J. D. Guanidinylated neomycin 
mediates heparin sulphate-dependent transport of active enzymes to lysozomes. Mol. 
Ther. 2010, 18, 1268-1274. 
(49) Dix, A. V.; Fischer, L.; Sarrazin, S.; Redgate, C. P. H.; Esko, J. D.; Tor, Y. 
Cooperative, heparan sulfate-dependent cellular uptake of dimeric guanidinoglycosides. 
ChemBioChem 2010, 11, 2302-2310. 
(50) Staple, D. W.; Venditti, V.; Niccolai, N.; Elson-Schwab, L.; Tor, Y.; Butcher, S. E. 
Guanidinoneomycin B recognition of an HIV-1 RNA helix. ChemBioChem 2008, 9, 93-
102. 
(51) Boer, J.; Blount, K. F.; Luedtke, N. W.; Elson-Schwab, L.; Tor, Y. RNA-selective 
modification by a platinum(II) complex conjugated to amino- and guanidinoglycosides. 
Angew. Chem. Int. Ed. 2005, 44, 927-932. 
(52) Michael, K.; Wang, H.; Tor, Y. Enhanced RNA binding of dimerized 
aminoglycosides. Bioorg. Med. Chem. 1999, 7, 1361-1371. 
(53) Riguet, E.; Désiré, J.; Bailly, C.; Décout, J-L. A route for preparing new neamine 
derivatives targeting HIV-1 TAR RNA. Tetrahedron, 2004, 60, 8053–8064. 
(54) Chaplin, A. B.; Dyson, P. J. Catalytic Activity of Bis-phosphine Ruthenium(II)-
Arene Compounds: Structure-Activity Correlations. Organometallics 2007, 26, 2447-
2455. 
(55) Baker, T. K.; Luedtke, N. W.; Tor, Y.; Goodman, M. Synthesis and anti-HIV 
activity of guanidinoglycosides. J. Org. Chem. 2000, 65, 9054-9058. 
(56) Egger, A. E.; Rappel, C.; Jakypec, M. A.; Hartinger, C. G.; Heffeter, P.; Keppler, 
B. K. Development of an experimental protocol for uptake studies of metal compounds 
in adherent tumor cells. J. Anal. At. Spectrom. 2009, 24, 51-64.  
(57) Groessl, M.; Zava, O.; Dyson, P. J. Cellular uptake and subcellular distribution of 
ruthenium-based metallodrugs under clinical investigation versus cisplatin. 
Metallomics, 2011, 3, 591-599. 
(58) Romero-Canelón, I.; Pizarro, A. M.; Habtemariam, A.; Sadler, P. J. Contrasting 
cellular uptake pathways for chlorido and iodido iminopyridine ruthenium arene 
anticancer complexes. Metallomics, 2012, 4, 1271-1279. 
(59) Ghezzi, A.; Aceto, M.; Cassino, C.; Gabano, E.; Osella, D. Uptake of antitumor 
platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass 
spectrometry (ICP-MS). J. Inorg. Biochem. 2004, 98, 73-78. 
 34
(60) Goun, E. A.; Pillow, T. H.; Jones, L. R.; Rothbard, J. B.; Wender, P. A. Molecular 
transporters: synthesis of oligoguanidinium transporters and their application to drug 
delivery and real-time imaging. ChemBioChem, 2006, 7, 1497-1515. 
(61) Wender, P. A.; Cooley, C. B.; Geihe, E. I. Beyond cell penetrating peptides: 
designed molecular transporters. Drug Discov. Today. 2012, 9, e49-e55. 
(62) Lattig-Tunnemann, G.; Prinz, M.; Hoffmann, D.; Behlke, J.; Palm-Apergi, C.; 
Morano, I,; Herce, H. D.; Cardoso, M. C. Backbone rigidity and static presentation of 
guanidinium groups increases cellular uptake of arginine-rich cell-penetrating peptides. 
Nat. Commun. 2011, 2, 453-458. 
(63) Reile, H.; Bernhardt, G.; Koch, M.; Schonenberger, H.; Hollstein, M.; Lux, F. 
Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-
diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation. 
Cancer Chemother. Pharmacol. 1992, 30, 113-122. 
(64) Bishop, J. R.; Schuksz, M.; Esko, J. D. Heparan sulphate proteoglycans fine-tune 
mammalian physiology. Nature, 2007, 446, 1030-1037. 
(65) Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Organometallic 
chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem. 
Commun. 2005, 4764-4776. 
 
 
Table of Contents Graphic 
 
 
